An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan versus standard of care chemotherapy as adjuvant treatment for patients with HER2-expressing (IHC 3+/2+) endometrial cancer: DESTINY-endometrial02 (DE-02)

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Cara Amanda Mathews, Charles E. Anderson, Nicoletta Colombo, Kosei Hasegawa, Jae-Hoon Kim, Katherine C. Kurnit, Michalis Liontos, Domenica Lorusso, Radoslaw Madry, Jyoti Mayadev, Andreia Melo, María Quindós
+8 more Joana G. Rodrigues, Barbara Schmalfeldt, Brian M. Slomovitz, Jianqing Zhu, Veronica Mariotti, Jojo Hara, Steven Ye Hua, Alexandra Leary
DOI: 10.1016/j.ijgc.2025.103197
Cited by: 1

Fields of Study & Subjects

HER2/EGFR in Cancer Research Endometrial and Cervical Cancer Treatments Angiogenesis and VEGF in Cancer

Publication details

Journal / source
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Volume
36
Issue
2
Pages
103197–103197
Publication date
1 February 2026
Language
EN